Objective: To evaluate the attachment rate of a human embryonic stem cell-derived trophoblastic spheroid onto endometrial epithelial cells in predicting the cumulative live birth rate of an in vitro fertilization (IVF) cycle.
Design: A prospective observational study.
Setting: University hospital and research laboratory.
Patient(s): A total of 240 infertile women from 2017-2021.
Intervention(s): Infertile women with regular cycles attending for IVF were recruited. An endometrial aspirate was collected from a natural cycle 1 month before IVF to determine the BAP-EB attachment rate.
Main Outcome Measure(s): Cumulative live birth rates from a stimulated cycle and its derived frozen embryo transfer cycles within 6 months of ovarian stimulation were obtained.
Result(s): The BAP-EB attachment rate in women who attained a cumulative live birth was similar to that in those who did not. When women were stratified by age into <35 years and ≥35 years, the BAP-EB attachment rate was significantly higher only in women aged ≥35 years having a live birth when compared with those in the same age group without a live birth. Receiver operating characteristic curve analysis of BAP-EB attachment rate in predicting cumulative live birth showed the areas under the curve of 0.559 (95% confidence interval [CI], 0.479-0.639), 0.448 (95% CI, 0.310-0.585), and 0.613 (95% CI, 0.517-0.710) for all ages, an age of <35 years, and an age of ≥35 years, respectively.
Conclusion(s): The BAP-EB attachment rate offers only a very modest prediction of the cumulative live birth rate in women aged ≥35 years undergoing IVF.
Clinical Trial Registration Number: NCT02713854 (https://clinicaltrials.gov/ct2/show/NCT02713854; Date of registration, March 21, 2016; date of enrollment of the first subject, August 1, 2017).
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.fertnstert.2023.03.013 | DOI Listing |
J Natl Cancer Inst
January 2025
UT Southwestern O'Donnell School of Public Health, Dallas, TX, USA.
Background: Few studies have examined childbirth and adverse perinatal outcomes among male adolescents and young adults with cancer (AYAs, diagnosed at age 15-39 years). We conducted a population-based assessment of these outcomes in a large, diverse sample.
Methods: Male AYAs diagnosed between January 1, 1995 and December 31, 2015 were identified using the Texas Cancer Registry and linked to live birth certificates and the Texas Birth Defects Registry through December 31, 2016.
Int J Womens Health
December 2024
Department of Traditional Chinese Medicine, Shenzhen Key Laboratory of Reproductive Immunology for Peri-Implantation, Shenzhen Zhongshan Institute for Reproductive Medicine and Genetics, Shenzhen Zhongshan Obstetrics & Gynecology Hospital (Formerly Shenzhen Zhongshan Urology Hospital), Shenzhen City, Guangdong Province, 518000, People's Republic of China.
Objective: This study analyzed the role of traditional Chinese medicine (TCM) treatment on the cumulative live birth rate (CLBR) in women with poor ovarian response to the patient-oriented strategies encompassing individualized oocyte number (POSEIDON) criteria.
Methods: This cohort study selected 3347 patients with low ovarian response and divided them into four subgroups according to the POSEIDON criteria: Group 1 (n=947), Group 2 (n=778), Group 3 (n=164), and Group 4 (n=1458). Logistic regression analysis was used to evaluate the role of TCM treatment on the CLBR of patients with poor ovarian response to POSEIDON criteria.
Front Endocrinol (Lausanne)
January 2025
Reproductive Medicine Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Objective: To build a prediction nomogram for early prediction of live birth probabilities according to number of oocytes retrieved in women ≤ 35 years of age.
Methods: A prediction model was built including 9265 infertile women ≤ 35 years of age accepting their first ovum pick-up cycle from January 2018 to December 2022. Least absolute shrinkage and selection operator (LASSO) regression was performed to identify independent predictors and establish a nomogram to predict reproductive outcomes.
Hum Reprod
December 2024
Department of Obstetrics and Gynecology, Center for Reproductive Medicine, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, Guangdong-Hong Kong-Macao Greater Bay Area Higher Education Joint Laboratory of Maternal-Fetal Medicine, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Study Question: Is there a difference in the cumulative live birth rate (CLBR) after fresh testicular sperm aspiration (TESA) compared with the use of either pre-frozen sperm or oocyte freezing for couples experiencing ejaculation failure on the day of oocyte retrieval?
Summary Answer: After adjusting for confounding factors, the use of pre-frozen sperm or the freezing and thawing of oocytes appeared to be as effective as TESA in achieving CLBRs for couples experiencing temporary ejaculation failure.
What Is Known Already: Male patients may be concerned about experiencing temporary ejaculation failure on the day of their partner's oocyte retrieval, in which case they may choose surgical sperm retrieval, oocyte freezing on the day, or have their sperm frozen in advance. However, the clinical efficacy of these three options has not yet been evaluated.
J Assist Reprod Genet
December 2024
Reproductive Medical Center, People's Liberation Army Joint Logistic Support Force 924Th Hospital, Guilin, Guangxi, People's Republic of China.
Purpose: Selection of optimal embryo transfer strategies for IVF patients treated with antagonist protocols.
Methods: A retrospective study was conducted to assess whether whole embryo culture to the blastocyst stage could enhance the cumulative live birth rate (CLBR). The study included data from the first oocyte retrieval cycle of 4131 patients who underwent IVF treatment between January 2018 and June 2022.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!